NCT06058377 2026-03-18Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNational Cancer Institute (NCI)Phase 3 Recruiting3,680 enrolled